Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.98 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.98 |
| ▸ | USP2 | O75604 | 2/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.98 |
| ▸ | LMNA | P02545 | 2/20 | 0.98 |
| ▸ | HPGD | P15428 | 2/20 | 0.98 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.98 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.98 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | SLC12A2 | P55011 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | ERAP1 | Q9NZ08 | 4/20 | 0.44 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piretanide SCHEMBL30230376 | 0.99 | KDM4E (1.00) | KDM4EHSD17B10USP2ALDH1A1LMNA | |
| Piretanide SCHEMBL1741994 | 0.99 | KDM4E (1.00) | KDM4EHSD17B10USP2ALDH1A1LMNA | |
| Piretanide SCHEMBL49473 | 0.99 | KDM4E (1.00) | KDM4EHSD17B10USP2ALDH1A1LMNA | |
| Piretanide SCHEMBL9837127 | 0.98 | KDM4E (0.98) | KDM4EHSD17B10USP2ALDH1A1LMNA | |
| Piretanide SCHEMBL7895002 | 0.97 | KDM4E (0.95) | KDM4EHSD17B10USP2ALDH1A1LMNA | |
| Piretanide SCHEMBL18075706 | 0.97 | KDM4E (0.95) | KDM4EHSD17B10USP2ALDH1A1LMNA | |
| SCHEMBL11542770 | 0.96 | KDM4E (0.95) | KDM4EHSD17B10USP2ALDH1A1LMNA | |
| SCHEMBL11546942 | 0.94 | LMNA (0.91) | KDM4EHSD17B10USP2ALDH1A1LMNA | |
| SCHEMBL11543210 | 0.91 | KDM4E (0.81) | KDM4EHSD17B10USP2ALDH1A1LMNA | |
| SCHEMBL11542957 | 0.91 | KDM4E (0.81) | KDM4EHSD17B10USP2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190151263-A1 | BUMETANIDE ANALGOS, COMPOSITIONS, AND METHODS OF USE | NEUROPRO THERAPEUTICS INC (US) | 2019-05-23 | — | — | US | disclosed |
| US-20170246131-A1 | BUMETANIDE ANALOGS, COMPOSITIONS, AND METHODS OF USE | NEUROPRO THERAPEUTICS INC (US) | 2017-08-31 | — | — | US | disclosed |
| US-20170246131-A1 | BUMETANIDE ANALOGS, COMPOSITIONS, AND METHODS OF USE | NEUROPRO THERAPEUTICS INC (US) | 2017-08-31 | — | — | US | disclosed |
| US-9682928-B2 | Bumetanide analogs, compositions and methods of use | NEUROPRO THERAPEUTICS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-9682928-B2 | Bumetanide analogs, compositions and methods of use | NEUROPRO THERAPEUTICS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-20150080350-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | NEUROPRO THERAPEUTICS INC. | 2015-03-19 | — | — | US | disclosed |
| US-20150080350-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | NEUROPRO THERAPEUTICS INC. | 2015-03-19 | — | — | US | disclosed |
| WO-2013059648-A1 | 2,3,5 TRISUBSTITUTED ARYL AND HETEROARYL AMINO DERIVATIVES, COMPOSITIONS, AND METHODS OF USE | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2013-04-25 | — | — | WO | disclosed |
| US-20120004225-A1 | BUMETANIDE, FUROSEMIDE, PIRETANIDE, AZOSEMIDE, AND TORSEMIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-20120004225-A1 | BUMETANIDE, FUROSEMIDE, PIRETANIDE, AZOSEMIDE, AND TORSEMIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| WO-2010085352-A2 | BUMETANIDE, FUROSEMIDE, PIRETANIDE, AZOSEMIDE, AND TORSEMIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2010-07-29 | — | — | WO | disclosed |
| US-4161531-A | Diuretic and saluretic 5-sulfamoylbenzoic acid derivatives carrying a heterocyclic substituent | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-07-17 | — | — | US | disclosed |
| US-4118397-A | DIURETICS | HOECHST AKTIENGESELLSCHAFT (DE) | 1978-10-03 | — | — | US | disclosed |
| US-4111953-A | DIURETICS | HOECHST AKTIENGESELLSCHAFT (DE) | 1978-09-05 | — | — | US | disclosed |
| US-4093735-A | DIURETICS | HOECHST AKTIENGESELLSCHAFT (DT) | 1978-06-06 | — | — | US | disclosed |
| US-4010273-A | DIURETICS, SALURETICS | HOECHST AKTIENGESELLSCHAFT (DT) | 1977-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170246131-A1 | BUMETANIDE ANALOGS, COMPOSITIONS, AND METHODS OF USE | SLC6A1, SLC6A13, SLC6A11 | KDM4E 2228/4885HSD17B10 1264/4885USP2 3353/4885 |
| US-20190151263-A1 | BUMETANIDE ANALGOS, COMPOSITIONS, AND METHODS OF USE | SLC6A1, SLC6A11, SLC6A13 | KDM4E 2764/4885HSD17B10 957/4885USP2 3646/4885 |
| US-20120004225-A1 | BUMETANIDE, FUROSEMIDE, PIRETANIDE, AZOSEMIDE, AND TORSEMIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | ABCG2, ABCB1, TRPV1 | KDM4E 3528/4885HSD17B10 3736/4885USP2 4684/4885 |
| US-20150080350-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | SLC6A1, SLC6A13, SLC6A11 | KDM4E 3717/4885HSD17B10 2879/4885USP2 4533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.